Dengue Fever Clinical Trials 2023

Dengue Fever Clinical Trials 2023

Dengue Fever research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in dengue fever clinical trials today.

Dengue Fever Clinical Trials

Here are the 0 most popular medical studies for dengue fever

Popular filter options for dengue fever trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to dengue fever

What are the top hospitals conducting dengue fever research?

In the battle against dengue fever, several prominent hospitals are making significant strides in clinical trials. One such institution is the State University of New york, Upstate Medical University (SUNY-UMU) in Syracuse. Though they currently have only one active trial for dengue fever, their commitment to research is evident with four all-time trials dedicated to tackling this mosquito-borne illness since their first recorded trial in 2015. Meanwhile, the University of Maryland's Center for Vaccine Development and Global Health in Baltimore has also joined the fight with one ongoing dengue fever trial and two previous studies conducted thus far. Impressively, they entered into this realm just last year recording their inaugural dengue fever trial in 2020.

Notably, Johns Hopkins University's Bloomberg School of Public Health located nearby has also made a notable contribution by initiating its first-ever dengue fever trial as recent as 2022. While still at an early stage with only one active trial ongoing currently, it reflects an unwavering dedication towards advancing our understanding and treatment options for this infectious disease.

Furthermore,, The Clinical Research Center at The University of Vermont Medical Center (UVMMC) situated in Burlington adds itself to this list by conducting its pioneering investigations on Dengue Fever from past couple years where like previously mentioned institutions even here had initiated single active testing along with same count when accounting prior experimentation back till respective start year20022

Although these hospitals may have relatively fewer trials compared to other conditions or diseases due to numerous factors associated specifically with studying dengue fever; each investigation serves as a crucial stepping stone toward finding effective prevention methods and treatments for this globally prevalent illness that affects millions each year.

Which are the best cities for dengue fever clinical trials?

When it comes to dengue fever clinical trials, three cities are leading the way in research. Baltimore, Maryland has 2 active trials focused on studying Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose and JNJ-64281802 among others. Syracuse, New york has 1 ongoing trial examining Cohort 1 Naive DENV1 and Burlington, Vermont also has 1 active trial investigating JNJ-64281802 alongside other interventions. These cities serve as hubs for cutting-edge dengue fever research, providing opportunities for advancements in treatment and prevention strategies.

Which are the top treatments for dengue fever being explored in clinical trials?

Clinical trials for dengue fever have been exploring a couple of promising treatments. One is the Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) at a low dose, which is currently being tested in one active trial. Another treatment to watch out for is JNJ-64281802 at a remaining high dose, also undergoing evaluation in one ongoing clinical trial. These innovative approaches hold potential in advancing the fight against dengue fever and bringing new hope to those affected by this mosquito-borne disease.

What are the most recent clinical trials for dengue fever?

Exciting advancements in dengue fever research are offering new possibilities for treatment. One recent clinical trial, Cohort 1 Naive DENV1, focuses on patients who have not been previously exposed to the DENV1 strain of the virus. This Phase 1 trial became available on 8/1/2023 and aims to evaluate the safety and efficacy of a potential treatment option. Another notable study is the Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose trial, which investigates the effects of exposing individuals to low doses of live dengue virus type 4. Although this Phase 1 trial became available earlier on 2/28/2022, it offers valuable insights into the development of future treatments. Lastly, JNJ-64281802 examines high-dose administration as part of its Phase 2 investigation into combating dengue fever; this trial was made available on February 3rd, 2022. These trials represent promising avenues in our ongoing battle against dengue fever.

What dengue fever clinical trials were recently completed?

In February 2019, the University of Pennsylvania concluded a clinical trial investigating the potential of INO-A002 for treating dengue fever. This recent completion signifies an important step in the ongoing efforts to combat this infectious disease.